Nader N El-Chaar
Overview
Explore the profile of Nader N El-Chaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swami U, Hong A, El-Chaar N, Ramaswamy K, Diessner B, Blauer-Peterson C, et al.
J Urol
. 2023 Feb;
209(6):1120-1131.
PMID: 36789668
Purpose: We evaluate utilization of treatment intensification of androgen deprivation therapy with androgen receptor pathway inhibitor/docetaxel for metastatic castration-sensitive prostate cancer patients across physician specialties. Materials And Methods: This retrospective...
2.
El-Chaar N, Smith T, Shrestha G, Piccolo S, Harper M, Wagoner R, et al.
Mar Drugs
. 2021 Jan;
19(1).
PMID: 33477536
Patients diagnosed with basal-like breast cancer suffer from poor prognosis and limited treatment options. There is an urgent need to identify new targets that can benefit patients with basal-like and...
3.
Shen Y, Rahman M, Piccolo S, Gusenleitner D, El-Chaar N, Cheng L, et al.
Bioinformatics
. 2015 Jan;
31(11):1745-53.
PMID: 25617415
Motivation: Although gene-expression signature-based biomarkers are often developed for clinical diagnosis, many promising signatures fail to replicate during validation. One major challenge is that biological samples used to generate and...
4.
El-Chaar N, Piccolo S, Boucher K, Cohen A, Chang J, Moos P, et al.
Mol Oncol
. 2014 Jun;
8(7):1339-54.
PMID: 24908424
Better approaches are needed to evaluate a single patient's drug response at the genomic level. Targeted therapy for signaling pathways in cancer has met limited success in part due to...